Table 4. Chemoimmunotherapy protocols for patients with metastatic squamous cell carcinoma and “nonsquamous” non-small-cell lung cancer (after exclusion of EGFR and ALK aberrations).

Protocol	Median survival [95% CI](months)	Risk reduction (HR)	Reference
Squamous cell carcinoma of the lung (PD-L1 TPS 0–100%)
Platinum/paclitaxel/nivolumab/Ipilimumab vs. platinum/paclitaxel	14.5 [13.1; 19.4] vs. 9.1 [7.2; 11.6]	0.62	(26)
Platinum/(nab-)paclitaxel/pembrolizumab vs. platinum/(nab-)paclitaxel/placebo	17.1 [14.4; 19.9] vs. 11.6 [10.1; 13.7]	0.71	(e34)
Platinum/gemcitabine or nab-paclitaxel/durvalumab/ tremelimumab vs. platinum/gemcitabine or nab-paclitaxel	10.4 [8.4; 12.7] vs. 10.5 [8.0; 11.7]	Not significant	(e37)
“Nonsquamous” lung cancer (PD-L1 TPS 0–100%)
Carboplatin/nab-paclitaxel/atezolizumab vs. carboplatin/nab-paclitaxel	18.6 [16.0; 21.2] vs. 13.9 [12.0; 18.7]	0.79	(e35)
Carboplatin/paclitaxel/bevacizumab/atezolizumab vs. carboplatinum/paclitaxel/bevacizumab	19.5 [17.0; 22.2] vs. 14.7 [12.9; 17.1]	0.8	(e36)
Platinum/pemetrexed/nivolumab/ipilimumab vs. platinum/pemetrexed	17.0 [14.0; n. e.] vs. 11.9 [9.9; 14.1]	0.69	(26)
Platinum/pemetrexed/pembrolizumab vs. platinum/pemetrexed/placebo	22.0 [19.5; 24.5] vs. 10.6 [8.7; 13.6]	0.56	(40)
Platinum/pemetrexed or nab-paclitaxel/durvalumab/ tremelimumab vs. platinum/pemetrexed or nab-paclitaxel	17.2 [14.9; 21.8] vs. 13.1 [10.6; 15.1]	0.7	(e37)
Non–small-cell lung cancer (PD-L1 TPS 50–100%)
Atezolizumab vs. platinum combinations	20.2 [n. r.] vs. 13.1 [n. r.]	0.59	(e15)
Cemiplimab vs. platinum combinations	n. a. [17.9; n. a.] vs. 14.2 [11.2; 17.5]	0.57	(e16)
Pembrolizumab vs. platinum combinations	26.6 [18.3; 40.4] vs. 13.4 [9.1; 18.3]	0.62	(24)

95% CI, 95% confidence interval; ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; HR, hazard ratio;

n. r., not reported; n. a., not attained at the time of publication; PD-L1, programmed cell death 1 ligand-1; TPS, tumor proportion score;

ROS1, ROS proto-oncogene 1; vs., versus